Altimmune Inc (ALT)

$4.30 +0.12 (2.87%)
Market Cap 418.41M
Revenue (ttm) 20,000.00
Net Income (ttm) -95.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475,300.00%
Debt to Equity Ratio 0.08
Volume 3,560,158
Avg Vol 4,506,554
Day's Range N/A - N/A
Shares Out 104.34M
Stochastic %K 67%
Beta 0.04
Analysts Strong Sell
Price Target $17.88

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
HattysRevenge
HattysRevenge Jan. 15 at 8:03 PM
$ALT My mind must have done a RESET ! We approached and breached the 25 million OS about the time of Spitfire acquisition ! šŸ¤·ā€ā™‚ļøšŸ¤« šŸ˜
0 Ā· Reply
BigCheeze2014
BigCheeze2014 Jan. 15 at 8:02 PM
$ALT Needs to go up by dollars!
0 Ā· Reply
Grumper
Grumper Jan. 15 at 8:01 PM
$ALT Hey Dursoā€”Everything is better with a partner!
0 Ā· Reply
YouGotitJobin
YouGotitJobin Jan. 15 at 7:59 PM
$ALT power hour! Letā€™s go to new HOD!
2 Ā· Reply
Dadschuh14
Dadschuh14 Jan. 15 at 7:57 PM
$ALT Could be WRONG here. Iā€™m seeing late day push to test above $4.40. Structure supports it!
0 Ā· Reply
LeeroyJenkins2
LeeroyJenkins2 Jan. 15 at 7:51 PM
$ALT PR will be coming from the buyer since they are purchasing ALTā€¦ with a PR from Dursley shortly after.
1 Ā· Reply
Grumper
Grumper Jan. 15 at 7:45 PM
$ALT So seems Durso is not going to PR eop2 fda meeting notes as someone posted last week (proprietary info they hold close). My understanding is P3 plans are aligned with FDA, but do we have actual FDA appproval to proceed? IMO this is ā€˜theā€™ binary eventā€” P3 has to start asap & Durso will need to reveal whether it is with a partner or gia.
0 Ā· Reply
Dadschuh14
Dadschuh14 Jan. 15 at 7:44 PM
$ALT Textbook shakeout is what I am seeing.
0 Ā· Reply
romanaround
romanaround Jan. 15 at 7:43 PM
$ALT these are the back to back 900k DP buys??
2 Ā· Reply
EcoDoc
EcoDoc Jan. 15 at 7:41 PM
$ALT Always a good day when this and $NLST are green. Lots to look forward to with both companies.
0 Ā· Reply
Latest News on ALT
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Jan 5, 2026, 7:30 AM EST - 10 days ago

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Dec 23, 2025, 7:42 PM EST - 22 days ago

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Dec 19, 2025, 12:57 PM EST - 27 days ago

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Dec 19, 2025, 11:37 AM EST - 27 days ago

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Dec 19, 2025, 6:42 AM EST - 27 days ago

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Dec 19, 2025, 6:30 AM EST - 27 days ago

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Altimmune Announces CEO Transition and Succession Plan

Dec 1, 2025, 7:30 AM EST - 6 weeks ago

Altimmune Announces CEO Transition and Succession Plan

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:30 AM EST - 7 weeks ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 3:03 PM EST - 2 months ago

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Altimmune: Probing Pemvi's MASH Data

Nov 14, 2025, 3:23 AM EST - 2 months ago

Altimmune: Probing Pemvi's MASH Data

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver MeetingĀ® 2025

Nov 11, 2025, 8:51 AM EST - 2 months ago

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver MeetingĀ® 2025

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver MeetingĀ® 2025

Nov 7, 2025, 8:05 AM EST - 2 months ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver MeetingĀ® 2025

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:26 PM EST - 2 months ago

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 7:00 AM EST - 2 months ago

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 2 months ago

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Nov 3, 2025, 7:30 AM EST - 2 months ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 30, 2025, 7:30 AM EDT - 2 months ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver MeetingĀ® 2025

Oct 20, 2025, 7:30 AM EDT - 3 months ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver MeetingĀ® 2025

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

Oct 6, 2025, 10:09 AM EDT - 3 months ago

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 5, 2025, 11:40 PM EDT - 3 months ago

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 3, 2025, 9:50 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 30, 2025, 10:20 AM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 29, 2025, 7:30 AM EDT - 3 months ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 21, 2025, 8:39 AM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

Sep 19, 2025, 10:27 AM EDT - 4 months ago

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

SLQT

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Sep 18, 2025, 8:45 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 15, 2025, 7:30 AM EDT - 4 months ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:20 AM EDT - 4 months ago

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Aug 27, 2025, 5:17 PM EDT - 5 months ago

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Altimmune to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:30 AM EDT - 5 months ago

Altimmune to Participate in Upcoming Investor Conferences

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Aug 19, 2025, 7:30 AM EDT - 5 months ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Aug 15, 2025, 12:06 PM EDT - 5 months ago

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:44 PM EDT - 5 months ago

Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Aug 13, 2025, 2:57 PM EDT - 5 months ago

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

HattysRevenge
HattysRevenge Jan. 15 at 8:03 PM
$ALT My mind must have done a RESET ! We approached and breached the 25 million OS about the time of Spitfire acquisition ! šŸ¤·ā€ā™‚ļøšŸ¤« šŸ˜
0 Ā· Reply
BigCheeze2014
BigCheeze2014 Jan. 15 at 8:02 PM
$ALT Needs to go up by dollars!
0 Ā· Reply
Grumper
Grumper Jan. 15 at 8:01 PM
$ALT Hey Dursoā€”Everything is better with a partner!
0 Ā· Reply
YouGotitJobin
YouGotitJobin Jan. 15 at 7:59 PM
$ALT power hour! Letā€™s go to new HOD!
2 Ā· Reply
Dadschuh14
Dadschuh14 Jan. 15 at 7:57 PM
$ALT Could be WRONG here. Iā€™m seeing late day push to test above $4.40. Structure supports it!
0 Ā· Reply
LeeroyJenkins2
LeeroyJenkins2 Jan. 15 at 7:51 PM
$ALT PR will be coming from the buyer since they are purchasing ALTā€¦ with a PR from Dursley shortly after.
1 Ā· Reply
Grumper
Grumper Jan. 15 at 7:45 PM
$ALT So seems Durso is not going to PR eop2 fda meeting notes as someone posted last week (proprietary info they hold close). My understanding is P3 plans are aligned with FDA, but do we have actual FDA appproval to proceed? IMO this is ā€˜theā€™ binary eventā€” P3 has to start asap & Durso will need to reveal whether it is with a partner or gia.
0 Ā· Reply
Dadschuh14
Dadschuh14 Jan. 15 at 7:44 PM
$ALT Textbook shakeout is what I am seeing.
0 Ā· Reply
romanaround
romanaround Jan. 15 at 7:43 PM
$ALT these are the back to back 900k DP buys??
2 Ā· Reply
EcoDoc
EcoDoc Jan. 15 at 7:41 PM
$ALT Always a good day when this and $NLST are green. Lots to look forward to with both companies.
0 Ā· Reply
Damnthisappilosthistory
Damnthisappilosthistory Jan. 15 at 7:35 PM
$ALT 2 questions: 1) does Durso wanna GIA or PS? 2) Will any BP overpay a multiple of current enterprise value?
0 Ā· Reply
BioRich
BioRich Jan. 15 at 7:29 PM
$ALT @Jcordless @ol_OTIS_supreme Again, you have absolutely no idea and I only share the truth. I live an amazing life, do basically everything I want and have an amazing and beautiful better half. Ya see, for someone like me, it doesn't take much effort to share truth. It's actually easy. $ALT is an easy one to figure out once you realize they present what they want you to see to keep you hanging on, not what the FDA, WS, SEC and BP want. Lies are stressful. Realizing you got scammed and not wanting to admit it is stressful. Looking out the window as I type this is not. Cheers chump. You got the wrong guy.
1 Ā· Reply
roadto2M
roadto2M Jan. 15 at 7:29 PM
$ALT direction confirmed
0 Ā· Reply
Muskvoice
Muskvoice Jan. 15 at 7:28 PM
$ALT $NOVO.X WE'RE READY FOR YOU https://seekingalpha.com/news/4538955-novo-nordisk-ceo-eying-deals-boost-obesity-drugs-portfolio?source=apple_news%253Anews
0 Ā· Reply
Muskvoice
Muskvoice Jan. 15 at 7:26 PM
$ALT ANOTHER 900K IN THE DARKPOOL TOTAL 1.8M IN THE LAST 30 MINUTES
2 Ā· Reply
GreenEnergy2022
GreenEnergy2022 Jan. 15 at 7:20 PM
$ALT Looks like we gonna close above 4.20 and all thats matters for a bullish continuation. My guess is also we will see a push up again before close.
0 Ā· Reply
Just_Brewski
Just_Brewski Jan. 15 at 7:19 PM
$ALT https://stocks.apple.com/AKNlGgNCzR6CTzYU59nPzSA
0 Ā· Reply
Muskvoice
Muskvoice Jan. 15 at 7:18 PM
$ALT
0 Ā· Reply
Stanleydavidson
Stanleydavidson Jan. 15 at 7:18 PM
$ALT Bring me all the penny im ready
0 Ā· Reply
Stanleydavidson
Stanleydavidson Jan. 15 at 7:15 PM
$ALT omg omg imnexited
0 Ā· Reply
Blink182rulez
Blink182rulez Jan. 15 at 7:13 PM
$ALT ok i guess i will sell some more $4.00 march exp calls, what do you guys think?
2 Ā· Reply
MINGZHU
MINGZHU Jan. 15 at 7:11 PM
$ALT leakingggg
0 Ā· Reply